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Abstract
Background: Islet transplantation has progressively become a safe alternative to pancreas transplantation for the
treatment of type 1 diabetes. However, the long-term results of islet transplantation could be significantly increased
by improving the quality of the islet isolation technique even exploring alternative islet transplantation sites to
reduce the number of islets required to mitigate hyperglycemia. The goal of the study was to test the lymph node
as a suitable anatomical location for islet engraftment in a rodent model.
Methods: Forty Lewis rats, 6–8 weeks old, body weight 250–300 g, have been used as islet donors and recipients in
syngeneic islet transplantation experiments. Ten rats were rendered diabetic by one injection of 65 mg/Kg of
streptozotocin. After pancreas retrieval from non diabetic donors, islet were isolated and transplanted in the
mesenteric lymph nodes of 7 diabetic rats. Rats were followed for 30 days after islet transplantation.
Results: A total of 7 islet transplantations in mesenteric lymph nodes have been performed. Two rats died 24 and
36 h after transplantation due to complications. No transplanted rat acquired normal glucose blood levels and
insulin independence after the transplantation. However, the mean blood levels of glycemia were significantly
lower in transplanted rats compared with diabetic rats (470.4 mg/dl vs 605 mg/dl, p 0.04). Interestingly, transplanted
rats have a significant weight increase after transplantation compared to diabetic rats (mean value 295 g in
transplanted rats vs 245 g in diabetic rats, p < 0.05), with an overall improvement of social activities and health.
Immunohistochemical analysis of the 5 mesenteric lymph nodes of transplanted rats demonstrated the presence of
living islets in one lymph node.
Conclusions: Although islet engraftment in lymph nodes is possible, islet transplantation in lymph nodes in rats
resulted in few improvements of glucose parameters.
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Background
Xenotransplantation has recently emerged as a promis-
ing alternative to contrast the increasing demand for
organ transplantation, and this resulted in many poten-
tial clinical applications [1], including the treatment of
type 1 diabetes. The dramatic impact on the health of
the world’s population has stimulated the need to de-
velop alternative strategies for the treatment of the type
1 diabetes [2]. Pancreatic islet transplantation is becom-
ing an increasingly important strategy for type 1 diabetes
mellitus treatment, with a growing number of new pro-
cedures performed worldwide, and is able to normalize
blood glucose or HbA1c levels in most recipients with
diabetes [3–9]. Transplantation of deceased human
donor islets into the portal vein in patients with type 1
diabetes mellitus has had encouraging results [3–11],
but is associated with an immediate loss of 60–80% of
islets through an inflammatory response known as the
instant blood-mediated inflammatory reaction (IBMIR)
[12, 13]. The long-term results of islet transplantation,
therefore, could be significantly increased by improving
the quality of the islet isolation technique to increase the
yield from the donor pancreas, or reducing the number
of islets required to improve hyperglycemia. In recent
years, many studies explored alternative islet transplant-
ation sites to reduce the number of islets required to
mitigate hyperglycemia [14–18].
The gastric sub-mucosal space (GSMS) is a promising
alternative site for islet implantation [14–16]: islets are
transplanted through an endoscopic placement, and they
would benefit from a rich blood supply and a high oxy-
gen tension. Preclinical trials using a porcine model
showed reduced early islet loss and insulin requirements
when GSMS islets were compared to intraportal islets
[14, 15], and islets were easily accessible for endoscopic
monitoring of graft rejection [16].
As alternative sites to the liver, Komori et al [19] dem-
onstrated the surprising potential of lymph nodes (LN)
as transplant sites for multiple tissues, among which
they also tested pancreatic islets. The goal of this study
was to conduct a pilot experiment of feasibility of islet
transplantation in the rat model. Following the results of
the study by Komori et al [19], where LN was success-
fully used for islet engraftment in a mouse model, we
tested, as a proof of concept, that successful engraftment
could be achieved in a larger rodent model.
Methods
Experimental procedures
Forty Lewis male rats (Charles River Laboratories, Calco,
Italy), 6–8 weeks old, body weight 250–300 g, have been
used as islet donors and recipients in syngeneic islet
transplantation experiments. From previous publications
[20, 21], we estimated that at least 3 pancreata were
needed for a single islet transplantation and, consequently,
rats were randomized on a 3:1 basis to serve as donor or
recipients of a islet transplantation. Ten rats were rendered
diabetic by one injection (i.v.) of 65mg/Kg of streptozoto-
cin (STZ), following the procedure described by Bottino et
al. [20]. Blood glucose was measured using a commercial
glucometer. Three consecutive blood glucose levels > 350
mg/dl following STZ administration confirmed the dia-
betic status. Being all syngeneic transplantations, recipients
did not receive immunosuppressive therapy.
The goal of the study was to test the lymph node as a
suitable anatomical location for islet engraftment. The
syngeneic transplantation model was chosen to deter-
mine whether the metabolic performance of islets was
sufficient to normalize hyperglycemia following trans-
plantation, warranting islet survival and function. Each
recipient received islets from 2 or 3 donors, with a total
of about 600–900 islets/recipient, depending on the
number and the quality of retrieved islets. All rats were
housed in microisolator caging in a specific pathogen
free environment under the guidelines of the Italian
National Institute of Health for animal care. All rats
were followed with daily measurement of body weight,
water intake and blood glycaemia. All surviving rats
were euthanized 30 days after transplantation, by the
means of CO2 inhalation at a flow rate set to 20% of the
chamber volume per minute.
Isolation and transplantation reagents
The isolation and transplantation reagents used for ex-
perimental procedures have been previously described in
details [21]. In brief, tissue culturing media consists of
RPMI 1640 media supplemented with 20 mM Hepes, 1%
L-glutamine, 1% penicillin/streptomycin, 50 μM b-merca
ptoethanol (2-ME) and 10% heat-inactivated fetal bovine
serum (FBS, Gibco®). Whole islets were maintained in
complete medium with a density of ~ 150 islets in 5 ml
medium at 37 °C in an atmosphere of 95% air and 5%
CO2. Media was replaced every 2–3 days. Due to vari-
ability in the activity of different lots of collagenase, all
collagenase used in this study (Collagenase type V) was
from a single lot. Hanks’ Balanced Salt Solution with cal-
cium and magnesium was supplemented with either 20
mM Hepes (HBSS-Hepes) or 20 mM Hepes plus 0.2%
BSA (HBSS-BSA) then filter sterilized. Ficoll was dis-
solved at the rate of 33.35 g Ficoll per 100 ml
HBSS-Hepes. All gradients are mixed thoroughly and
stored at 4 °C.
Organ procurement
Donor rat was sacrificed immediately before pancreas is
procured through CO2 inhalation at a flow rate set to
20% of the chamber volume per minute. The procure-
ment and isolation procedure was carried out under
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sterile conditions in a biological safety cabinet. A lapar-
otomy is performed and the skin and body wall are
pulled back toward the head. The liver is reflected back
against the diaphragm. The common bile duct is located
and tied off at the papilla of Vater to prohibit flow from
the bile duct into the intestine. A 10 ml syringe is filled
with cold collagenase solution and a 25G needle is at-
tached. The needle is inserted into the bile duct, close to
the liver with the needle pointed toward the intestine
(Fig. 1). The needle is inserted into the bile duct as far
as possible without further damaging the duct (no other
punctures). The collagenase is injected into the pancreas
until it is fully and visibly distended (Fig. 2). Depending
on the size of the animal, the inflation may take 5–8 ml
of collagenase. After inflation, the pancreas is removed
by tearing and cutting away from the attached tissue and
ducts. For maximum yield, attention is paid to remove
the entire pancreas.
Islet isolation protocol
The procedure has been previously described in detail
[21]. In brief, the excised pancreas is washed in cold col-
lagenase solution, then placed in a 25 cm2 flask and kept
on ice until all other pancreata are procured. Usually, no
more than two pancreata are placed in one flask. An
additional 2–4 ml collagenase is also placed in the flask
before incubation. The flask is incubated at 37 °C for
20–25min without shaking. After incubation the flask is
shaken sharply to disrupt the tissue. The digested tissue
is placed in a 50 ml conical tube and filled to 50ml with
HBSS-BSA to wash. The tubes are gently centrifuged at
1100 Revolutions Per Minute (RPM) for 1 min to pellet
the tissue. The supernatant is removed without disturb-
ing the loosely compacted pellet. It is washed twice more
and the supernatant is removed. The tissue is mixed
with 25% type 400 Ficoll and a density gradient is con-
structed by overlaying solutions of 23, 20.5% and finally
11% Ficoll. After centrifugation, collect the interface
from each density and wash away the Ficoll with
HBSS-BSA solution. Place the collected tissue in a 60mm
non-tissue culture sterile Petri dish. The islets are then
handpicked to eliminate any remaining exocrine tissue
and immediately counted after isolation by microscopy
(Fig. 3). Individual rat islets may range from smaller than
50 to over 400 μm in size; the adult animals used in this
study generally had islets in the same proportionate size
ranges. On average, this isolation method reliably recovers
150–300 islets from an adult rat (> 25 g body weight).
Whole islets, are maintained in complete medium at 37 °C
in a humidified atmosphere of 95% air and 5% CO2.
Islet transplantation in recipient diabetic rats
The procedure was carried out under sterile conditions.
The animals are, first of all, anesthetized with gaseous
anesthesia (isofloran/oxygen mixture 2–4% 1–2 L/min)
and a laparotomy is performed; a surgical retractor is used
to improve the access and visibility of the abdominal cav-
ity. The bowel is pulled out and the mesenteric lymph
nodes are located. The islets, previously loaded into a 1.5
ml tube with their proper medium, are slowly injected into
the mesenteric lymph node by using a cannula (Fig. 4). To
provide some indications of the approximate site of the
islet transplant, a 5–0 Prolene® marking stitch is applied.
The bowel is repositioned back into the abdominal cavity.
The body wall is sutured with 6–0 Nylon. The procedure
is completed in about 15min. The animals are kept warm
until recovery from anesthesia.
Necropsy was performed in all transplanted animals. Bi-
opsies of the transplanted and non-transplanted LN were
performed for microscopic examination for the presence
of insulin-positive cells. Tissues were fixed in 10% buffered
formalin, and paraffin sections were stained with
hematoxylin and eosin (H&E) insulin and glucagon, using
standard procedures. Immunofluorescence studies
Fig. 1 The needle is inserted into the bile duct (arrow)
Fig. 2 The collagenase is injected into the pancreas until it is fully
and visibly distended. A green vegetable dye is added to the
collagenase for visibility
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(TUNEL) for apoptosis were carried out on frozen sec-
tions. The pathologist (LP) was blinded to result analysis.
Lymph nodes were treated with 10% formalin for 24–
48 h and for immunohistochemical analyses. Each sam-
ple was treated with Anti-Insulin Antibodies, (Dako,
Glostrup, Denmark); anti-sinaptofisina, clone SY38
(Dako, Glostrup, Denmark); anti-chromogranin A,
(Dako, Glostrup, Denmark); anti-CD68, clone PG-M1
(Dako, Glostrup, Denmark); anti-CD68, clone KP1
(Dako, Glostrup, Denmark).
The primary outcome of the study was the return to
euglycemia without the need of insulin therapy, in dia-
betic rats undergoing islet transplantation; and, demon-
strating viable islets in recovered lymph nodes.
All the experiments were conducted by the same in-
vestigators (LV, RB, SB, MV).
Statistical analysis
Levels of glycemic were expressed as mean values and
comparison of means pre- and post- islet transplantation
were estimated by the unpaired two Student’s t-test or
Mann-Whitney U test, as appropriate. p value < 0.05 was
considered as statistically significant. All calculations
were performed using SPSS, version 12.0.
Results
A total of 7 islet transplantations in mesenteric lymph
nodes have been performed. Two rats died 24 and 36 h
after transplantation due to complications.
Three groups of rats were considered:
○ Group A: three diabetic rats;
○ Group B: three non-diabetic rats (controls);
○ Group C: five diabetic rats receiving islet
transplantation.
Five transplanted rats survived until euthanasia
through CO2 inhalation. No transplanted rat acquired
normal glucose blood levels and insulin independence
after the transplantation. However, the mean blood
levels of glycemia were significantly lower in trans-
planted rats compared with diabetic rats (470.4 mg/dl vs
605 mg/dl, p 0.04). Interestingly, transplanted rats have a
significant weight increase after transplantation com-
pared to diabetic rats (mean value 295 g in transplanted
rats vs 245 g in diabetic rats, p < 0.05) (Fig. 5), with an
overall improvement of social activities and health.
There was no significant correlation between the num-
ber of transplanted islets and levels of glycemia.
As expected, there was no evidence of islet in mesen-
teric lymph-nodes in group A and B rats.
Immunohistochemical analysis of the 5 mesenteric
lymph nodes of transplanted rats demonstrated the pres-
ence of living islets in one lymph node (Fig. 6), as con-
firmed by the presence of insulin-positive cells (Fig. 7) and
anti-sinaptofisina, clone SY38 and anti-chromogranin A
Fig. 3 Islets (arrows) seen at the microscope (a), and after coloration with dithizone (b)
Fig. 4 The islets are slowly injected into the mesenteric lymph node
by using a cannula (arrow)
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analyses (Fig. 8). In other transplanted lymph-nodes, there
was no evidence of intact islet cells, but only macrophage
elements positive for insulin, suggesting the existence of
necrotic or apoptotic islets (Fig. 9).
Discussion
The research for alternative transplant sites plays a funda-
mental role in the field of pancreatic islet transplantation
and, in general, of cellular transplantation. The results re-
ported by several previous studies show the gastric sub-
mucosal space is one of the most promising sites that
could be clinically used in the near future [14–16]. How-
ever, this assumption does not appear to be completely
valid for the lymph nodes, whose use in islet transplant-
ation is possible but it may be intended to better
characterize the mechanism of allo- and xeno-transplant-
ation of pancreatic islets in animal models.
The present study allowed obtaining more information
about some aspects of the islet transplantation already
highlighted by previous studies. The intent to prove
whether the anatomical location of the lymph nodes af-
fects islet survival and function was inspired by Komori’s
work [19], who hypothesized and evaluated the surpris-
ing potential of lymph nodes as transplantation sites for
multiple tissues. In their work, Komori et al [19],under-
lined the interesting properties of the lymph nodes: their
specific environment protects and enhances survival of
lymphocytes, they are close to blood vessels and they
also contain fibroblastic reticular cells and other stromal
cells that secrete chemokines. They engrafted three dis-
tinct healthy cell types, hepatocytes, thymic tissue and
pancreatic islets, in different lymph nodes of mice and
they observed their ability to promote survival and
growth of transplanted cells [19]. Syngeneic mouse
Fig. 5 Change in body weight in experimental groups; STZ + islet (transplanted rats); STZ (diabetic rats not transplanted); ctrl (controls)
Fig. 6 Hematoxylin and eosin section demonstrating the presence
of viable islets into the lymph node Fig. 7 Insulin positive cells in transplanted lymph-node
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hepatocytes marked with green fluorescent protein were
injected into the single large jejunal lymph node – it was
selected because it is easily accessible and it is the largest
in the mouse; one week after injection, the cells were
retained mainly in the subcapsular sinus of the lymph
node rather than the follicles or germinal centres and,
additionally, they formed patches of tissue accompanied
by remodelling of blood vessels and growth [19, 22].
Similarly, they injected thymic tissue into the same
lymph node of athymic mice and ten months after they
observed its long-term engraftment, confirmed by dem-
onstrating that a T-cell-dependent immunity had been
acquired by the recipients [19, 22]. Concerning pancre-
atic islets, the study showed successful islet transplant-
ation in a diabetic syngeneic mouse model, by the
infusion of 300 mouse islets mixed with Matrigel into
the jejunal lymph node of mice treated with streptozoto-
cin; as well as the hepatocytes, the islets were found in
the subcapsular sinus of the lymph node and the expres-
sion of C-peptide was detected. Six weeks after trans-
plantation the authors observed the normalization of
blood glucose in the recipients, demonstrating the sur-
vival of pancreatic islets and the ability of the lymph
nodes to sustain long-term normoglycaemia [19, 22].
Then, according to the immunological role of the lymph
nodes, they hypothesize that an immune response might
interfere with the function of the engrafted cells, so they
induced an inflammatory reaction in the intraperitoneal
cavity of normoglycaemic recipients with an injection of
lipopolysaccharide: they observed a temporary reduction
in mouse weight and blood glucose levels, but any in-
crease in glucose blood levels above normal levels was
observed, which meant functioning grafts [19, 22]. These
data suggested that the lymph nodes did not have nega-
tive effects on grafted islets. Their analysis included two
other important findings: they observed many endothe-
lial cells expressed by grafted islet around the areas of
the engraftment, suggesting that extensive vascular
remodelling takes place during the engraftment [19];
additionally, they detected markers of neovascular re-
modelling in each of the engrafted lymph nodes, sug-
gesting that blood vessels surrounding the lymph nodes
also contribute to the neovascularization [19]. These ob-
servations allow the establishment of the lymph node as
a new potential site for functional cellular transplant,
taking account of other properties in addition to those
already mentioned: its accessibility and the possibility to
monitor cells’ function by its biopsy or even its excision;
Fig. 8 Chromogranin staining examination demonstrated the presence of viable β pancreatic cells (a) with no α-cells (b)
Fig. 9 Immunohistochemical analyses demonstrated absence of intact islets/beta cells (a), with macrophages elements positive for insulin (b)
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moreover, in the islet transplantation, another advantage
could be the secretion of insulin directly into the portal
circulation by using the lymph nodes of the abdominal
cavity. The results of the present study, at least in part,
confirm the hypothesis by Komori and colleagues [19],
considering the following evidences: a) the blood glucose
levels in transplanted rats were significantly lower than
those in diabetic rats; b) transplanted rats’ weight was
increased after islet transplantation; c) transplanted rats’
social activities and health were improved after trans-
plantation; d) living islets were immunohistochemically
demonstrated in one mesenteric lymph node. However,
although the studies by Komori’s group [19] suggest that
the lymph nodes are a suitable site for islet transplant-
ation, it is at the same time possible that the lymph node
may represent an adverse and more immunogenic site
and that in the absence of immunosuppression allogen-
eic islets may be rejected very rapidly, and this is prob-
ably independent by the site used. This possibility would
explain a fifth evidence of the present study: e) why in
some transplanted lymph-nodes there was no evidence
of liable islet cells, but only macrophage elements posi-
tive for insulin, suggesting the islet apoptosis. If this
proves to be the case, nevertheless syngeneic islets show
prolonged survival and function, we will still progress to
studies in cynomolgus monkeys where immunosuppres-
sive therapy will be administered, in contrast to rats
which do not tolerate well immunosuppression.
Conclusions
Our study demonstrated that, although islet engraftment
in lymph nodes is possible, islet transplantation in lymph
nodes in rats resulted in few improvements of glucose pa-
rameters. Nevertheless, this study provided a step forward
in the knowledge of the mechanisms of islet engraftment.
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